Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Neoplasms and AXL[original query] |
---|
Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status. Biomedical reports 2014 Jul 2 (4): 481-489. Yu DA-Ping, Dong Yu-Jie, Zhang Hai-Qing, Wang Jing-Hui, Qu Yang, Zhou Li-Juan, Su Dan, Zhang Li-Li, Zhao Dan, Cai Yi-R |
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. Oncology letters 2016 Feb 11 (2): 1223-1229. Zhang Shu-Dong, McCrudden Cian M, Yuen Hiu-Fung, Leung Ka Lai, Hong Wan-Jin, Kwok Hang F |
Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes. Oncology letters 2016 Nov 12 (5): 3312-3322. Cai Yi-Ran, Dong Yu-Jie, Wu Hong-Bo, Yu Da-Ping, Zhou Li-Juan, Su Dan, Zhang Li, Chen Xue-Ji |
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer research 2017 9 77 (22): 6119-6130. Sivakumar Smruthy, Lucas F Anthony San, McDowell Tina L, Lang Wenhua, Xu Li, Fujimoto Junya, Zhang Jianjun, Futreal P Andrew, Fukuoka Junya, Yatabe Yasushi, Dubinett Steven M, Spira Avrum E, Fowler Jerry, Hawk Ernest T, Wistuba Ignacio I, Scheet Paul, Kadara Hum |
Epigenetic regulation of AXL and risk of childhood asthma symptoms. Clinical epigenetics 2017 9 121. Gao Lu, Millstein Joshua, Siegmund Kimberly D, Dubeau Louis, Maguire Rachel, Gilliland Frank D, Murphy Susan K, Hoyo Cathrine, Breton Carrie |
BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS biology 2018 8 16 (8): e2005756. Najafov Ayaz, Zervantonakis Ioannis K, Mookhtiar Adnan K, Greninger Patricia, March Ryan J, Egan Regina K, Luu Hoang Son, Stover Daniel G, Matulonis Ursula A, Benes Cyril H, Yuan Junyi |
Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. BMC cancer 2018 Jul 18 (1): 739. Berg Janna, Halvorsen Ann Rita, Bengtson May-Bente, Taskén Kristin A, Mælandsmo Gunhild M, Yndestad Arne, Halvorsen Bente, Brustugun Odd Terje, Aukrust Pål, Ueland Thor, Helland Åsla |
Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine 2018 Feb . Karachaliou Niki, Chaib Imane, Cardona Andres Felipe, Berenguer Jordi, Bracht Jillian Wilhelmina Paulina, Yang Jie, Cai Xueting, Wang Zhigang, Hu Chunping, Drozdowskyj Ana, Servat Carles Codony, Servat Jordi Codony, Ito Masaoki, Attili Ilaria, Aldeguer Erika, Capitan Ana Gimenez, Rodriguez July, Rojas Leonardo, Viteri Santiago, Molina-Vila Miguel Angel, Ou Sai-Hong Ignatius, Okada Morihito, Mok Tony S, Bivona Trever G, Ono Mayumi, Cui Jean, Ramón Y Cajal Santiago, Frias Alex, Cao Peng, Rosell Rafa |
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clinical lung cancer 2019 2 20 (3): e317-e328. Nokihara Hiroshi, Nishio Makoto, Yamamoto Noboru, Fujiwara Yutaka, Horinouchi Hidehito, Kanda Shintaro, Horiike Atsushi, Ohyanagi Fumiyoshi, Yanagitani Noriko, Nguyen Linh, Yaron Yifah, Borgman Anne, Tamura Tomohi |
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas. Molecular cancer 2019 2 18 (1): 24. Tsukita Yoko, Fujino Naoya, Miyauchi Eisaku, Saito Ryoko, Fujishima Fumiyoshi, Itakura Koji, Kyogoku Yorihiko, Okutomo Koji, Yamada Mitsuhiro, Okazaki Tatsuma, Sugiura Hisatoshi, Inoue Akira, Okada Yoshinori, Ichinose Masaka |
Differences in Genomic Alterations Between Brain Metastases and Primary Tumors. Neurosurgery 2020 Dec . Dono Antonio, Takayasu Takeshi, Yan Yuanqing, Bundrant Bethany E, Arevalo Octavio, Lopez-Garcia Carlos A, Esquenazi Yoshua, Ballester Leomar |
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. Journal of hematology & oncology 2021 7 14 (1): 107. Bill Marius, Mrózek Krzysztof, Giacopelli Brian, Kohlschmidt Jessica, Nicolet Deedra, Papaioannou Dimitrios, Eisfeld Ann-Kathrin, Kolitz Jonathan E, Powell Bayard L, Carroll Andrew J, Stone Richard M, Garzon Ramiro, Byrd John C, Bloomfield Clara D, Oakes Christopher |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung cancer (Amsterdam, Netherlands) 2021 4 155 127-135. Park Keunchil, Chang Gee-Chen, Curigliano Giuseppe, Lim Wan-Teck, Soo Ross A, Molina-Vila Miguel A, Cattan Valérie, Darville Hélène, Gandossi Eric, Smutna Veronika, Sudey Isabelle, Viteri Santia |
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood advances 2021 3 5 (5): 1540-1551. Renosi Florian, Roggy Anne, Giguelay Ambre, Soret Lou, Viailly Pierre-Julien, Cheok Meyling, Biichle Sabeha, Angelot-Delettre Fanny, Asnafi Vahid, Macintyre Elizabeth, Geffroy Sandrine, Callanan Mary, Petrella Tony, Deconinck Eric, Daguindau Etienne, Harrivel Véronique, Bouyer Sabrina, Salaun Véronique, Saussoy Pascale, Feuillard Jean, Fuseau Pascal, Saas Philippe, Adotévi Olivier, Jardin Fabrice, Ferrand Christophe, Preudhomme Claude, Colinge Jacques, Roumier Christophe, Garnache-Ottou Franci |
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. Cancer science 2022 9 114 (2): 606-618. Yoshimura Akihiro, Yamada Tadaaki, Serizawa Masakuni, Uehara Hisanori, Tanimura Keiko, Okuma Yusuke, Fukuda Akito, Watanabe Satoshi, Nishioka Naoya, Takeda Takayuki, Chihara Yusuke, Takemoto Shinnosuke, Harada Taishi, Hiranuma Osamu, Shirai Yukina, Shukuya Takehito, Nishiyama Akihiro, Goto Yasuhiro, Shiotsu Shinsuke, Kunimasa Kei, Morimoto Kenji, Katayama Yuki, Suda Kenichi, Mitsudomi Tetsuya, Yano Seiji, Kenmotsu Hirotsugu, Takahashi Toshiaki, Takayama Koic |
LZTR1 mutation mediates oncogenesis through stabilization of EGFR and AXL. Cancer discovery 2022 11 . Ko Aram, Hasanain Mohammad, Oh Young Taek, D'Angelo Fulvio, Sommer Danika, Frangaj Brulinda, Tran Suzanne, Bielle Franck, Pollo Bianca, Paterra Rosina, Mokhtari Karima, Soni Rajesh Kumar, Peyre Matthieu, Eoli Marica, Papi Laura, Kalamarides Michel, Sanson Marc, Iavarone Antonio, Lasorella An |
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer immunology, immunotherapy : CII 2023 1 . Morimoto Kenji, Yamada Tadaaki, Sawada Ryo, Azuma Koichi, Goto Yasuhiro, Harada Taishi, Shiotsu Shinsuke, Tamiya Nobuyo, Chihara Yusuke, Takeda Takayuki, Hiranuma Osamu, Hasegawa Isao, Tanaka Satomi, Yoshimura Akihiro, Iwasaku Masahiro, Tokuda Shinsaku, Kim Young Hak, Takayama Koic |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: